Phase II trial of a GM-CSF-producing and CD40L-expressing bystander cell line combined with an allogeneic tumor cell-based vaccine for refractory lung adenocarcinoma

We created a vaccine in which irradiated allogeneic lung adenocarcinoma cells are combined with a bystander K562 cell line transfected with hCD40L and hGM-CSF. By recruiting and activating dendritic cells, we hypothesized that the vaccine would induce tumor regression in metastatic lung adenocarcino...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Creelan, Ben C., Antonia, Scott, Noyes, David, Hunter, Terri B., Simon, George R., Bepler, Gerold, Williams, Charles C., Tanvetyanon, Tawee, Haura, Eric B., Schell, Michael J., Chiappori, Alberto
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2013
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3846277/
https://ncbi.nlm.nih.gov/pubmed/23994887
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CJI.0b013e3182a80237
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi